-transparent.png){kind=logo}
The long-term safety and antihypertensive efficacy of carteolol were evaluated in an open-label, multicenter trial of 245 hypertensive patients. For those patients maintained on carteolol monotherapy, three months of treatment with once-daily oral doses of carteolol ranging from 2.5 to 60 mg reduced the mean recumbent blood pressure by 12/14 mm Hg from baseline values of 151/100. Blood pressure reductions observed at three months were maintained throughout the study. The final daily dose of carteolol for most patients was 10 mg or less. Carteolol was shown to be safe and well tolerated by most patients.
Related Publications
R R Luther, and
C J Maurath, and
M J Klepper, and
R O Peckinpaugh, and
G L Ringham
November 1975,
Postgraduate medicine,
R R Luther, and
C J Maurath, and
M J Klepper, and
R O Peckinpaugh, and
G L Ringham
January 1988,
Journal of cardiovascular pharmacology,
R R Luther, and
C J Maurath, and
M J Klepper, and
R O Peckinpaugh, and
G L Ringham
January 1983,
Arzneimittel-Forschung,
R R Luther, and
C J Maurath, and
M J Klepper, and
R O Peckinpaugh, and
G L Ringham
December 1994,
Journal of human hypertension,
R R Luther, and
C J Maurath, and
M J Klepper, and
R O Peckinpaugh, and
G L Ringham
February 2003,
Journal francais d'ophtalmologie,
R R Luther, and
C J Maurath, and
M J Klepper, and
R O Peckinpaugh, and
G L Ringham
January 1991,
Journal of cardiovascular pharmacology,
R R Luther, and
C J Maurath, and
M J Klepper, and
R O Peckinpaugh, and
G L Ringham
April 1982,
The American journal of cardiology,
R R Luther, and
C J Maurath, and
M J Klepper, and
R O Peckinpaugh, and
G L Ringham
November 1985,
International journal of clinical pharmacology, therapy, and toxicology,
R R Luther, and
C J Maurath, and
M J Klepper, and
R O Peckinpaugh, and
G L Ringham
January 1984,
Minerva cardioangiologica,
R R Luther, and
C J Maurath, and
M J Klepper, and
R O Peckinpaugh, and
G L Ringham
September 2003,
Clinical therapeutics,
